Michael Grunebaum
Associate Professor of Psychiatry at Columbia University Irving Medical Center; Research Psychiatrist at the New York State Psychiatric Institute
Data updated
Research Footprint
Michael Grunebaum appears in 5 tracked papers (2017–2022), most studied alongside Ketamine, Esketamine and Placebo, across Depressive Disorders, Bipolar Disorder and Suicidality.
Most-cited paper: Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial (423 citations).
Frequent co-authors: Carlos Zarate, Todd Gould and Mark Andrew Frye.
Background & Research
Michael F. Grunebaum, MD, is a psychiatrist and clinical researcher at Columbia University focused on mood disorders, suicidal behavior, and treatment studies. He earned his MD from Harvard Medical School and completed psychiatry training in New York, later joining Columbia/New York State Psychiatric Institute, where he has led and co-led multiple ketamine studies.
Key Impact
He is a leading ketamine and suicidality researcher whose clinical trials and meta-analytic work helped shape rapid-acting antidepressant research in psychiatry.
Collaboration Network
17 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Michael Grunebaum is associated with.
Columbia University
academicResearch with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.
View stakeholder →New York State Psychiatric Institute
State-funded psychiatric research institute affiliated with Columbia University, located in New York City. A key site for psilocybin clinical trials including the landmark COMP360 study for treatment-resistant depression, and conducts broader research on LSD, DMT, ayahuasca, and ketamine through Columbia's Depression Evaluation Service.
View stakeholder →